KRYSTAL BIOTECH INC(NASDAQ:KRYS) stock Fundamental Analysis

Fundamental Rating

We assign a fundamental rating of 6 out of 10 to KRYS. KRYS was compared to 571 industry peers in the Biotechnology industry. KRYS is in great health and has no worries on liquidiy or solvency at all, but the profibility rating is only average. KRYS has a decent growth rate and is not valued too expensively.

Quickly go to:

1. Profitability

1.1 Basic Checks

KRYS had positive earnings in the past year.

In the past year KRYS had a positive cash flow from operations.

The reported net income has been mixed in the past 5 years: KRYS reported negative net income in multiple years.

In the past 5 years KRYS reported 4 times negative operating cash flow.

1.2 Ratios

KRYS's Return On Assets of 8.44% is amongst the best of the industry. KRYS outperforms 95.89% of its industry peers.

KRYS has a better Return On Equity (9.42%) than 95.36% of its industry peers.

KRYS has a better Return On Invested Capital (9.64%) than 95.71% of its industry peers.

		Industry Rank	Sector Rank
ROA	8.44%
ROE	9.42%
ROIC	9.64%

ROA(3y)-5.09%

ROA(5y)-7.35%

ROE(3y)-5.33%

ROE(5y)-7.74%

ROIC(3y)N/A

ROIC(5y)N/A

1.3 Margins

The Profit Margin of KRYS (30.69%) is better than 98.04% of its industry peers.

KRYS's Operating Margin of 35.52% is amongst the best of the industry. KRYS outperforms 98.93% of its industry peers.

KRYS's Gross Margin of 93.09% is amongst the best of the industry. KRYS outperforms 93.93% of its industry peers.

		Industry Rank	Sector Rank
OM	35.52%
PM (TTM)	30.69%
GM	93.09%

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3YN/A

GM growth 5YN/A

More info and screens

ROA

ROE

ROIC

Operating and Profit Margin

Show most profitable peers

2. Health

2.1 Basic Checks

KRYS has a Return on Invested Capital (ROIC), which is just above the Cost of Capital (WACC), which means it is creating some value.

KRYS has more shares outstanding than it did 1 year ago.

KRYS has more shares outstanding than it did 5 years ago.

KRYS has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.

2.2 Solvency

An Altman-Z score of 29.34 indicates that KRYS is not in any danger for bankruptcy at the moment.

With an excellent Altman-Z score value of 29.34, KRYS belongs to the best of the industry, outperforming 96.07% of the companies in the same industry.

KRYS has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.

		Industry Rank	Sector Rank
Debt/Equity	0
Debt/FCF	0
Altman-Z	29.34

ROIC/WACC1.03

WACC9.32%

2.3 Liquidity

A Current Ratio of 7.28 indicates that KRYS has no problem at all paying its short term obligations.

KRYS's Current ratio of 7.28 is fine compared to the rest of the industry. KRYS outperforms 68.57% of its industry peers.

A Quick Ratio of 7.02 indicates that KRYS has no problem at all paying its short term obligations.

With a decent Quick ratio value of 7.02, KRYS is doing good in the industry, outperforming 67.86% of the companies in the same industry.

		Industry Rank	Sector Rank
Current Ratio	7.28
Quick Ratio	7.02

More info and screens

WACC

Debt/Equity

How to determine the health of a company

Altman-Z score

Show peers with great health

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 187.94% over the past year.

Looking at the last year, KRYS shows a very strong growth in Revenue. The Revenue has grown by 472.97%.

EPS 1Y (TTM)187.94%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%406.67%

Revenue 1Y (TTM)472.97%

Revenue growth 3YN/A

Revenue growth 5YN/A

Sales Q2Q%116.26%

3.2 Future

The Earnings Per Share is expected to grow by 34.03% on average over the next years. This is a very strong growth

The Revenue is expected to grow by 35.37% on average over the next years. This is a very strong growth

EPS Next Y100.74%

EPS Next 2Y78.62%

EPS Next 3Y41.98%

EPS Next 5Y34.03%

Revenue Next Year57.7%

Revenue Next 2Y51.34%

Revenue Next 3Y44.59%

Revenue Next 5Y35.37%

3.3 Evolution

More info and screens

Find the best growth stocks

Show best growing peers

4. Valuation

4.1 Price/Earnings Ratio

With a Price/Earnings ratio of 57.16, KRYS can be considered very expensive at the moment.

Based on the Price/Earnings ratio, KRYS is valued cheaply inside the industry as 93.21% of the companies are valued more expensively.

Compared to an average S&P500 Price/Earnings ratio of 29.98, KRYS is valued quite expensively.

KRYS is valuated quite expensively with a Price/Forward Earnings ratio of 28.47.

Based on the Price/Forward Earnings ratio, KRYS is valued cheaply inside the industry as 92.68% of the companies are valued more expensively.

KRYS is valuated rather expensively when we compare the Price/Forward Earnings ratio to 22.66, which is the current average of the S&P500 Index.

		Industry Rank	Sector Rank
PE	57.16
Fwd PE	28.47

4.2 Price Multiples

Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of KRYS indicates a rather cheap valuation: KRYS is cheaper than 94.11% of the companies listed in the same industry.

Based on the Price/Free Cash Flow ratio, KRYS is valued cheaply inside the industry as 93.93% of the companies are valued more expensively.

		Industry Rank	Sector Rank
P/FCF	41.24
EV/EBITDA	39.17

4.3 Compensation for Growth

KRYS's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.

The decent profitability rating of KRYS may justify a higher PE ratio.

KRYS's earnings are expected to grow with 41.98% in the coming years. This may justify a more expensive valuation.

PEG (NY)0.57

PEG (5Y)N/A

EPS Next 2Y78.62%

EPS Next 3Y41.98%

More info and screens

Show best valued peers

5. Dividend

5.1 Amount

KRYS does not give a dividend.

		Industry Rank	Sector Rank
Dividend Yield	N/A

More info and screens

Find the best dividend stocks

Show peers with best dividend

KRYSTAL BIOTECH INC

NASDAQ:KRYS (3/3/2025, 3:45:55 PM)

170.895

-8.35 (-4.66%)

Chartmill FA Rating

GICS SectorHealth Care

GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences

GICS IndustryBiotechnology

Earnings (Last)02-19 2025-02-19/bmo

Earnings (Next)05-05 2025-05-05/bmo

Inst Owners99.71%

Inst Owner Change-0.42%

Ins Owners11.97%

Ins Owner Change-1.57%

Market Cap4.91B

Analysts83.75

Price Target210.38 (23.1%)

Short Float %12.41%

Short Ratio11.59

Dividend

		Industry Rank	Sector Rank
Dividend Yield	N/A

Yearly DividendN/A

Dividend Growth(5Y)N/A

DPN/A

Div Incr Years0

Div Non Decr Years0

Ex-DateN/A

Surprises & Revisions

EPS beat(2)1

Avg EPS beat(2)13.47%

Min EPS beat(2)-0.73%

Max EPS beat(2)27.68%

EPS beat(4)1

Avg EPS beat(4)-15.87%

Min EPS beat(4)-80.01%

Max EPS beat(4)27.68%

EPS beat(8)2

Avg EPS beat(8)-14.64%

EPS beat(12)5

Avg EPS beat(12)-8.57%

EPS beat(16)7

Avg EPS beat(16)-8.54%

Revenue beat(2)0

Avg Revenue beat(2)-1.08%

Min Revenue beat(2)-1.26%

Max Revenue beat(2)-0.9%

Revenue beat(4)1

Avg Revenue beat(4)-0.79%

Min Revenue beat(4)-6.45%

Max Revenue beat(4)5.47%

Revenue beat(8)N/A

Avg Revenue beat(8)N/A

Revenue beat(12)N/A

Avg Revenue beat(12)N/A

Revenue beat(16)N/A

Avg Revenue beat(16)N/A

PT rev (1m)0%

PT rev (3m)-0.74%

EPS NQ rev (1m)38.3%

EPS NQ rev (3m)40.78%

EPS NY rev (1m)-0.88%

EPS NY rev (3m)0.61%

Revenue NQ rev (1m)9.8%

Revenue NQ rev (3m)7.43%

Revenue NY rev (1m)-1.06%

Revenue NY rev (3m)-1.03%

Valuation

		Industry Rank	Sector Rank
PE	57.16
Fwd PE	28.47
P/S	16.92
P/FCF	41.24
P/OCF	39.82
P/B	5.19
P/tB	5.19
EV/EBITDA	39.17

EPS(TTM)2.99

EY1.75%

EPS(NY)6

Fwd EY3.51%

FCF(TTM)4.14

FCFY2.42%

OCF(TTM)4.29

OCFY2.51%

SpS10.1

BVpS32.91

TBVpS32.91

PEG (NY)0.57

PEG (5Y)N/A

Profitability

		Industry Rank	Sector Rank
ROA	8.44%
ROE	9.42%
ROCE	10.82%
ROIC	9.64%
ROICexc	25.81%
ROICexgc	25.81%
OM	35.52%
PM (TTM)	30.69%
GM	93.09%
FCFM	41.02%

ROA(3y)-5.09%

ROA(5y)-7.35%

ROE(3y)-5.33%

ROE(5y)-7.74%

ROIC(3y)N/A

ROIC(5y)N/A

ROICexc(3y)N/A

ROICexc(5y)N/A

ROICexgc(3y)N/A

ROICexgc(5y)N/A

ROCE(3y)N/A

ROCE(5y)N/A

ROICexcg growth 3YN/A

ROICexcg growth 5YN/A

ROICexc growth 3YN/A

ROICexc growth 5YN/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3YN/A

GM growth 5YN/A

F-Score6

Asset Turnover0.28

Health

		Industry Rank	Sector Rank
Debt/Equity	0
Debt/FCF	0
Debt/EBITDA	0
Cap/Depr	63.12%
Cap/Sales	1.46%
Interest Coverage	250
Cash Conversion	112.29%
Profit Quality	133.67%
Current Ratio	7.28
Quick Ratio	7.02
Altman-Z	29.34

F-Score6

WACC9.32%

ROIC/WACC1.03

Cap/Depr(3y)534.57%

Cap/Depr(5y)974.6%

Cap/Sales(3y)N/A

Cap/Sales(5y)N/A

Profit Quality(3y)N/A

Profit Quality(5y)N/A

High Growth Momentum

Growth

EPS 1Y (TTM)187.94%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%406.67%

EPS Next Y100.74%

EPS Next 2Y78.62%

EPS Next 3Y41.98%

EPS Next 5Y34.03%

Revenue 1Y (TTM)472.97%

Revenue growth 3YN/A

Revenue growth 5YN/A

Sales Q2Q%116.26%

Revenue Next Year57.7%

Revenue Next 2Y51.34%

Revenue Next 3Y44.59%

Revenue Next 5Y35.37%

EBIT growth 1Y206.14%

EBIT growth 3YN/A

EBIT growth 5YN/A

EBIT Next Year267.71%

EBIT Next 3YN/A

EBIT Next 5YN/A

FCF growth 1Y218.47%

FCF growth 3YN/A

FCF growth 5YN/A

OCF growth 1Y238.98%

OCF growth 3YN/A

OCF growth 5YN/A

KRYSTAL BIOTECH INC (KRYS) Stock Fundamental Analysis

1. Profitability

1.1 Basic Checks

1.2 Ratios

1.3 Margins

More info and screens

2. Health

2.1 Basic Checks

2.2 Solvency

2.3 Liquidity

More info and screens

3. Growth

3.1 Past

3.2 Future

3.3 Evolution

More info and screens

4. Valuation

4.1 Price/Earnings Ratio

4.2 Price Multiples

4.3 Compensation for Growth

More info and screens

5. Dividend

5.1 Amount

More info and screens